Mark Joseph Enyedy's most recent trade in Charles River Laboratories International Inc. was a trade of 2,082 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Charles River Laboratories... | Mark Joseph Enyedy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 2,082 | 2,082 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | Mark Joseph Enyedy | Director | Grant, award, or other acquisition of securities at price $ 135.04 per share. | 02 Jun 2025 | 946 | 946 (0%) | 0% | 135.0 | 127,748 | Common Stock |
| Biomarin Pharmaceutical In... | Mark Joseph Enyedy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 6,650 | 13,550 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Mark Joseph Enyedy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 6,900 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Joseph Enyedy Mark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2023 | 2,180 | 2,180 (0%) | 0% | 0 | Common Stock | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 4.05 per share. | 30 Jun 2023 | 5,241 | 441,449 (0%) | 0% | 4.0 | 21,226 | Common Stock |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 922,400 | 922,400 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 153,700 | 153,700 | - | - | Restricted Stock Unit | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 3.82 per share. | 30 Jun 2022 | 3,342 | 436,208 (0%) | 0% | 3.8 | 12,783 | Common Stock |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 787,500 | 1,181,250 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 393,750 | 393,750 | - | - | Stock Option (Right to Buy) | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 1,100,000 | 1,100,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 5.52 per share. | 30 Jun 2021 | 3,849 | 432,866 (0%) | 0% | 5.5 | 21,246 | Common Stock |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 925,000 | 925,000 | - | - | Stock Option (right to buy) | |
| Immunogen, Inc. | Mark Joseph Enyedy | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Feb 2021 | 10,000 | 429,017 (0%) | 0% | 0 | Common Stock |